Palladon Injectie (Hydromorphone Hydrochloride)

Hydromorphone hydrochloride, the active ingredient in Palladon Injectie, is an opioid analgesic presented as an injectable solution for parenteral use. It is employed in the management of moderate to severe pain, particularly in postoperative settings and in patients requiring continuous analgesia. GNH USA supplies Palladon Injectie as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Palladon Injectie as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Palladon Injectie contains hydromorphone, an opioid that acts on the central nervous system to relieve pain. It is indicated for: - Post‑operative pain: provides rapid, controllable analgesia after surgery. - Cancer‑related pain: helps manage moderate to severe pain in oncology patients. - Acute severe pain: used when fast onset of relief is required, such as in trauma or severe injury. - Chronic pain requiring opioid rotation: may be employed when switching from another opioid to maintain analgesic control.

Hydromorphone may cause a range of adverse reactions, from mild to potentially life‑threatening.

Common Side Effects: - Nausea and vomiting: frequent gastrointestinal response. - Constipation: reduced bowel motility. - Drowsiness or sedation: central nervous system depression. - Dry mouth: decreased salivation. - Pruritus: itching, often localized. - Dizziness: light‑headed sensation.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing. - Severe hypotension: marked drop in blood pressure. - Bradycardia: unusually slow heart rate. - Allergic reactions: rash, swelling, or anaphylaxis. - Urinary retention: difficulty emptying the bladder. - Seizures: rare neurologic events.

When using Palladon Injectie, clinicians should observe several safety measures.

- Assess pain level and opioid tolerance: tailor dosing to individual needs. - Monitor respiratory function: watch for signs of depression, especially after initiation. - Evaluate renal and hepatic function: adjust use in impairment. - Avoid concurrent CNS depressants: limit additive sedation risk. - Educate patients on dependence potential: discuss safe use and storage. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Hydromorphone can interact with various medications, altering its efficacy or safety profile.

Major Interactions (Avoid): - Benzodiazepines: combined use can cause profound respiratory depression. - Barbiturates: additive central nervous system depression. - Muscle relaxants: increased risk of sedation and respiratory compromise.

Moderate Interactions (Monitor Closely): - Anticholinergics: may worsen constipation. - CYP3A4 inhibitors (e.g., ketoconazole): can raise hydromorphone plasma levels. - CYP3A4 inducers (e.g., rifampicin): may reduce analgesic effect.